In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enantigen Therapeutics Inc.

Division of Arbutus Biopharma Corp.

Latest From Enantigen Therapeutics Inc.

Start-Up Quarterly Statistics, Q4 2014

In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.

BioPharmaceutical Medical Device

Tekmira Merges With OnCore In Hopes Of Building Hepatitis B Powerhouse

The two small biotechs are coming together to create a hepatitis B-focused company that management hopes will mirror the success seen with hepatitis C companies.

BioPharmaceutical North America

Deals Shaping The Medical Industry, November 2014

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arbutus Biopharma Corp.
  • Senior Management
  • Michael X Xu, PhD, Pres. & COO
    Kathy Czupich, VP, Bus. Dev.
    Andrea Cuconati, PhD, VP, Biology
  • Contact Info
  • Enantigen Therapeutics Inc.
    Phone: (215) 589-6350
    3805 Old Easton Rd.
    Doylestown, PA 18902